Wild-type human p53 and a series of p53 point mutants isolated from Burkitt's lymphoma (BL) cell lines were tested for their ability to inhibit DNA synthesis in a p53-negative BL cell line and to bind and be degraded by the human papillomavirus type 16 E6 protein. All the mutants lost the wild-type ability to inhibit DNA synthesis, demonstrating that they are all functionally altered. Binding to E6 and consequent degradation of the p53 mutants frequently correlated with changed suppressor properties in BL cells.
Introduction
Mutations within the p53 tumour suppressor gene have been detected in a wide range of different human tumours and are the most common genetic change detected in human cancers (Hollstein et aI., 1991) . The majority of mutations identified are single base substitutions resulting in the alteration of one amino acid within one of the evolutionarily conserved regions of the p53 protein. The observation that mutation usually results in the expression of an altered protein, rather than complete loss of p53, suggests that mutant p53 proteins have an activity other than loss of wild-type p53 function. Support for this hypothesis has been provided by experimental studies showing transforming activities of mutant p53 genes in p53-negative cells (Shaulsky et al., 1991) . Transfection studies in rodent cells have demonstrated positive transforming activities of many p53 mutants which appear to be separable from the loss of wild-type ability to suppress transformation in the same cell systems (Hinds et al., 1992; Farrell et al., 1991) .
Expression studies have shown that in many cases point mutation within p53 results in the stabilization of the protein leading to an overexpression of p53 in tumour cells (Lane & Benchimol, 1990) . The basis for this stabilization is not understood but it is of interest that p53 is targeted by the transforming proteins encoded by small DNA tumour viruses and that these interactions also affect p53 stability (Levine, 1990) . Adenovirus, simian virus 40 (SV40) and oncogenic human papillomavirus (HPV) types such as HPV-16 and -18 all encode oncoproteins which form a complex with wild-type p53 (Lane & Crawford, 1979; Sarnow et al., 1982; Werness et al., 1990) . This complex formation is thought to prevent wild-type p53 function and so relieve the negative control of cell growth normally exerted by p53. Although interaction with each viral protein may lead to loss of p53 function, the consequence of the virus-p53 protein interaction for p53 stability differs considerably. SV40 large T antigen interaction results in the stabilization of p53 (Yewdell et al., 1986 ) and binding to E6 of HPV leads to the rapid proteolytic degradation of p53 (Scheffner et al., 1990) . E6-directed degradation of p53 requires at least one other cell protein (Huibregtse et al., 1991) and involves the ubiquitin-directed proteolytic pathway, a mechanism by which p53 may normally be turned over in an uninfected cell (Ciechanover et al., 1991) . We have shown recently that some mutant p53 proteins identified in anogenital cancers have a reduced ability to bind E6 and therefore display some resistance to E6-directed degradation (Crook & Vousden, 1992) . This may reflect a change in the interactions of p53 with other cell proteins, although no correlation between transforming activity in rodent cells and ability to be targeted for degradation by E6 in an in vitro assay could be identified.
We and others recently found that p53 is frequently mutated in Burkitt's lymphoma (BL) cell lines (Farrell et al., 1991; Gaidano et al., 1991 ; Wiman et al., 1991) . Analysis of several of these mutant p53s in primary rodent epithelial cells revealed a range of activities from suppression of transformation, through loss of suppressor activity to acquisition of dominant transforming activity (Farrell et al., 1991) . In this study we have assayed the activity of these mutant p53 proteins in Akata ceils, a p53-negative BL cell line representative of the cell type from which the mutants were isolated. We have also examined the ability of the mutant p53 proteins to form a complex with the HPV-16 E6 protein and subsequently be degraded, to assess whether this activity correlates with altered biological activity in the relevant cell type.
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Methods
Construction ofAkata/p53 transfectants. The p53 cDNAs described earlier (Farrell et al., 1991) were subcloned into pMEP4 from the pJ4f~ constructs using the BglII and HindIII polylinker sites in pJ4f~ and the BamHI and HindIII polylinker sites in pMEP4 (Invitrogen). This leaves the p53 correctly oriented in pMEP4 for expression from the metallothionein promoter in that vector. Plasmid DNAs were electroporated into Akata cells (Takada & Ono, 1989) and hygromycinresistant lines were selected as described elsewhere (Lau et al., 1992) . The cells were maintained in RPMI-1640 containing 10 % fetal calf serum and 0.3 mg/ml hygromycin B.
Western blotting. Cells were lysed in SDS sample buffer, electrophoresed on SDS-polyacrylamide gels and blotted to nitrocellulose. p53 was detected using PAbl801 (see below) and the Amersham ECL system. Typically about 8 x 10 ~ cells were resuspended in 200 gl of SDS sample buffer, sonicated, boiled and 50 lal was loaded per lane.
[3H]Thymidine incorporation assays. Cells were maintained in exponential growth by dilution every 1 to 2 days for at least 7 days prior to labelling. Normally 75 lal of cell culture (about 4 x 104 cells) was mixed in a well of a 96-well microtitre plate with 75 gl of complete medium with or without CdC1 e to give a final CdC12 concentration of 5 gM. After incubation for 24 h at 37 °C, 50 gl of medium containing 0.4 gCi of [aH]thymidine was added and incubation continued for a further 4 h at 37 °C. Cells were then harvested onto filters using the Skatron semiautomatic harvester and the dried filters were scintillationcounted. Duplicate wells were sampled for each cell line in two experiments and the mean ratios of thymidine incorporation after 24 h incubation with ( + CdC12) and without (-CdC12) CdC12 and standard deviations are shown in Fig. 2 . Typical results for BL2 were about 250000 d.p.m, for -CdC12 and about 70000 d.p.m, for +CdCI~.
Transfections of primary rat cells. Baby rat kidney (BRK) cells were prepared and transfected with plasmids encoding mutant p53 sequences using calcium phosphate coprecipitation as previously described . Cells were cotransfected with 5 gg of each test plasmid, 5 gg pJ4~E7, 5 lag pEJ6.6 and 1.5 gg pSV2neo. Selection for transfected cells was carried out using 0"3 mg/ml G418 and colonies of transformed cells were scored after 2 to 3 weeks.
E6 binding and degradation.
Wild-type and mutant p53 and HPV-16 E6 protein were synthesized following in vitro transcription and translation in a rabbit reticulocyte lysate as previously described (Crook et al., 1991b) . For binding experiments, the E6 protein was translated in the presence of [35S]cysteine and the p53 proteins were labelled with [35S]methionine. Equal amounts of each p53 protein were mixed with E6 in 100 mM-NaC1, 0-1 M-Tris HC1 pH 8-0, 1% NP40 and allowed to incubate on ice for 1 to 2 h. The p53 E6 complexes were immunoprecipitated using the monoclonal antibody (MAb) PAbl801 (Banks et al., 1986) , an antibody recognizing an N-terminal epitope of p53 distant from the position of any of the mutations, and Protein A or Protein ~Sepharose as previously described (Crook et al., 1991 b) . Coprecipitated proteins were resolved by PAGE and levels of binding quantified by densitometric scanning, making allowance for variation in p53 input. Assays for E6-directed degradation were carried out by mixing in vitro translated E6 and p53 in 25 mM-Tris-HC1 pH 7.5, 100 mM-NaC1, 3 mM-DTT and incubating at 30 °C or 37 °C for 0 to 3 h. For studies at 37 °C, proteins were equilibrated for 10 min at 37 °C prior to E6 addition. The p53 protein remaining after incubation with E6 was resolved by PAGE either with or without prior immunoprecipitation with PAbl801, equivalent results being obtained using either protocol. The extent of p53 degradation was assessed by densitometric scanning of the autoradiograms.
Results
Inducible expression of p53 in a p53-negative BL cell line
Although the mutant p53s detected in BL cell lines have previously been assayed for transformation and suppressor activities in rodent cells (Farrell et al., 1991) , it would be more appropriate to determine the effect of expressing these proteins in human B lymphocytes. Most of the cell lines in which the mutations were originally identified showed deletion of the second p53 allele and so did not express any wild-type p53 protein. These assays were therefore carried out in Akata cells, a BL cell line previously shown not to express p53 (Farrell et al., 1991) , to avoid any influence of endogenous wild-type p53 protein. Expression of wild-type p53 in normal or transformed cells has been shown to arrest progress through the cell cycle and is incompatible with continued cell growth (Baker et aI., 1990; Diller et al., 1990; Mercer et al., 1990) . To examine the effects of expressing wildtype and mutant p53 proteins in Akata cells, we therefore used a system which allowed inducible expression of the p53 proteins following transfection and isolation of cell lines. The p53 sequences were placed under the control of the metallothionein promoter in a vector containing the Epstein-Barr virus origin of replication and a dominant selectable marker. Transfections and subsequent drug selection were carried out without induction of p53 expression and several independently derived pools of transfected ceils were isolated for each p53 plasmid. Hirt supernatants (Hirt, 1967) were assayed by Southern blotting and revealed approximately the same copy number of episomally maintained plasmid in each of the lines (data not shown). Induction of p53 proteins was achieved by adding 5 [tM-cadmium chloride to the culture medium and protein expression was normally assayed by Western blotting 24 h after addition of cadmium chloride. Five independently derived pools of cells transfected with wild-type p53 were shown to induce about the same level of p53, whereas uninduced cells expressed no detectable p53 protein (Fig. 1 a) . A truncated form of p53 was also observed in all the inductions. We are unsure whether this is a degradation product of the full-length p53 or a result of erroneous initiation or termination of translation from the cDNA, which lacks some of the normal 5' and 3' untranslated sequences of p53 mRNA. A similar band has been detected in other cell lines overexpressing p53 with several different anti-p53 antibodies (Rodrigues et al., 1990; Gannon et al., 1990) . Levels of p53 protein expression following cadmium induction were similar to the high levels seen in Ramos cells (Fig. 1 b) , one of the BL cell lines in which a mutant p53 was originally detected. Increased levels of p53 protein were detected by Western blotting 4 h after (Fig. 1 c) . Similar studies with cell lines transfected with the m u t a n t p53 plasmids showed that b r o a d l y c o m p a r a b l e levels of p53 protein were expressed after induction (Fig. 1 a, d and e) although levels of P3HR1 p53 were reproducibly slightly lower. N o correlation between phenotype and level of p53 expression was observed between different lines expressing the same p53 m u t a n t so it appears that the a m o u n t o f p53 being p r o d u c e d is not limiting. C o m p a r i s o n of m u t a n t p53 proteins revealed slight differences in mobility reflecting the p o l y m o r p h i s m at a m i n o acid 72.
Transfections of primary rat cells
Our previous studies showed that expression of wild-type p53 could suppress t r a n s f o r m a t i o n by adenovirus E l a or HPV-16 E7 in c o o p e r a t i o n with ras in B R K cells, whereas transfection with mutant p53s derived from BL cell lines showed a range of phenotype from suppression to enhancement of transformation (Farrell et al., 1991) . In this original study, Ramos mutant p53 was found to suppress transformation by both HPV-16 E7 and adenovirus Ela and was thus indistinguishable from wild-type p53 in this assay. Subsequent analyses have revealed, however, that the p53 clone used for those studies had acquired a frameshift mutation during PCR cloning which resulted in the expression of a truncated protein. The authentic Ramos p53 mutant carrying only the Ile to Asp substitution at position 254 has now been tested in the BRK assay and shown to have lost suppressor activity and possibly gained a slight positive transforming function as measured by the ability to enhance E7 plus ras transformation (Table 1) . This corrected version of the Ramos p53 mutant has been used in all further experiments. The p53 mutant derived from Jijoye cells was also tested in this assay and similarly shown to have lost suppressor and gained some transforming activity (Table 1) .
Activities of mutant and wild-type p53 in Akata cells
The effect of expressing p53 protein on growth of Akata cells was assessed by measuring [aH]thymidine incorporation following cadmium induction. Initial experiments showed that expression of wild-type p53 resulted in a decrease in DNA synthesis which was seen most clearly after a 24 h induction with cadmium. Longer exposure to cadmium (48 to 72 h) resulted in a nonspecific inhibition of growth characterized by a reduction in aH incorporation in all cells including those transfected by vector sequences only (data not shown). Comparisons of DNA synthesis in cells expressing wild-type and mutant p53 proteins were therefore made following a 24 h exposure to cadmium. Expression of wild-type p53 reduced [aH]thymidine incorporation to approximately 20 to 50 % of that seen in cells transfected by vector sequences only (Fig. 2) , presumably reflecting the negative effect of wild-type p53 on cell growth. The ability to cause this substantial arrest of cell growth was lost by all the mutant p53s tested and no consistent difference could be detected between them (Fig. 2) . None of the mutant p53s increased the rate of DNA synthesis above that seen for control Akata cells. The microscopic appearance of the Akata cell line containing the inducible wild-type p53 construct was studied over a 3 day period of induction by CdC12. By the third day there was extensive cell death. A myeloid leukaemia cell line growth-arrested by p53 has been reported to die by apoptosis (Yonish-Rouach et al., 1991) . However, 24 h after addition of CdC12, when DNA synthesis has been arrested, there was no visible difference between the treated and control Akata cells containing inducible wild-type p53. In addition, agarose gel electrophoresis of DNA from the cells treated with CaC12 for 24 h showed no evidence of the nucleosomal ladders of cleaved DNA characteristic of apoptosis (data not shown). It therefore appears that the inhibition of DNA synthesis by p53 in these BL cells occurs before any apoptotic or other cell death. The uniform phenotype displayed by the different mutant p53s in the Akata cell assay is in contrast to the variable activities displayed in the rodent cell transformation assay, where the Ramos and P3HR1 mutants showed evidence of dominant transforming activity. In BRK cells, the BL41 mutant lost suppressor activity without gaining transforming activity but Raji and BL37 retained suppressor activity and were indistinguishable from wild-type p53.
HPV-16 E6-directed degradation of p53
Wild-type p53 is able to form a complex with the HPV-16 E6 protein , resulting in the rapid degradation of p53 (Scheffner et al., 1990) . This association is thought to be one of the mechanisms by which HPV-16 interferes with normal cell growth control and the ability to interact with E6 may reflect an important normal function of p53, perhaps related to the rapid turnover of the wild-type protein. The mutant p53 proteins described in this study were assayed for their ability to be degraded following complex formation with E6 to determine whether this activity correlated with phenotypes displayed by these mutants when expressed in rodent epithelial or human B cells. All the mutant p53s tested, with the exception of Raji, showed a reduction in E6 binding compared to wild-type protein (Table 2) . BL37 p53 displayed a modest reduction in binding whereas BL41, Ramos and P3HR1 p53 showed a more severe loss of the ability to complex E6. These binding activities were essentially reflected in the ability of these mutant p53s to be targeted for degradation by E6 (Table  2 , Fig. 3 ) where only the Raji protein is degraded like wild-type p53. Other p53 mutants showed varying degrees of resistance to degradation, Ramos p53 being the most clearly resistant. These assays were carried out at 30 °C because previous studies suggested that degradation of p53 is most efficient at this temperature (Scheffner et al., 1990) . Recent reports, however, have suggested that some human mutant p53 proteins may be temperature-sensitive, displaying a wild-type conformation at 30 °C and a mutant conformation at 37 °C (Medcalf et al., 1992) . We therefore also performed degradation assays at 37°C to test Raji p53 for temperature-dependent sensitivity to E6-directed degradation. As reported by Scheffner et al. (1990) , degradation at 37 °C was less efficient in these in vitro assays than that measured at 30 °C and more consistent differences between degradation at the two temperatures were seen when degradation was assayed after 1 h, before complete degradation of wild-type p53 at 30 °C (Table  2) . Although the wild-type degradation of Raji p53 was confirmed at 30 °C, this mutant showed significantly enhanced resistance to degradation at 37 °C.
Discussion
Sequence analyses have demonstrated the presence of mutations within the p53 gene of many different human cancers and it is generally assumed that expression of these mutant p53 proteins contributes to malignant development. Although many different missense mutations in p53 have been identified, relatively few have been examined for alterations in biological activities such as the ability to suppress or enhance transformation. A high proportion of BL cell lines had previously been shown to carry mutations within the p53 gene but transfection of these mutant p53s into primary rodent epithelial cells showed that few of them exhibited a dominant transforming activity. Some of the BL-derived p53 mutants lost suppressor activity without gaining transforming activity and others retained the ability to suppress transformation, behaving indistinguishably from wildtype p53 in this assay. To examine this apparent range of activities more closely in a relevant cell type we have determined the effect of expressing wild-type and mutant p53 proteins on DNA synthesis in Akata cells, a p53-negative BL cell line. In contrast to the activities assayed in rodent cells, all the mutant p53s showed a similar loss of the wild-type ability to depress thymidine incorporation into DNA. The ability of wild-type p53 to reduce DNA synthesis is consistent with previous studies showing arrest of cell growth following expression of p53. Although the levels of p53 protein induced in these studies are clearly much higher than seen for wild-type p53 during the normal cell cycle, our studies suggest that they are comparable with levels of mutant p53 protein seen in BL cell lines and a recent proposal for the normal role of p53 (Lane, 1992 ) is based on the high level of expression of wild-type p53 in response to DNA damage.
None of the p53 mutants tested showed any ability to increase DNA synthesis compared to control Akata cells and no evidence for a positive growth-enhancing activity could be detected in this assay. The variation in activities in the rodent and human cell assays could reflect the difference in cell type used or differences in phenotype being assayed. Akata cells do not express p53 and may have acquired compensatory mutations in other genes controlling cell growth, masking potentially growthpromoting effects of the mutant p53 proteins. It will therefore be worthwhile to assess the activity of these mutant p53 proteins in untransformed lymphoblastoid cell lines expressing endogenous wild-type p53. Our results also show for the first time that inhibition of DNA synthesis by wild-type human p53 occurs in cells carrying the translocated myc locus characteristic of BL, which may be of interest since one potential function of p53 is in transcriptional control of growth regulatory proteins (Fields & Jang, 1990; Raycroft et al., 1990; Ginsberg et al., 1991) . It is clear from our studies that mutant p53s identified in human cancer cell lines show alterations in growth suppressing or promoting activities when compared to wild-type p53, but that these differences depend on the cell type in which the assay is carried out as well as the specific type of mutation involved. We have therefore used an in vitro assay to examine another property of p53, the ability to be targeted for degradation by HPV-16 E6, to determine whether this activity could be p53 mutants in Burkitt's lymphoma cells 809 correlated with any of the effects on cell growth. In general, the acquisition of resistance to degradation correlated well with the loss of ability to depress DNA synthesis in Akata cells, whereas the more complex range of phenotypes assayed in primary rodent cells was not clearly reflected in the degradation assay. The Raji p53 mutant (Arg to Gln at residue 213) showed some temperature sensitivity for resistance to degradation and it may be of interest to determine whether expression of Raji p53 at 30 °C in Akata cells results in a reduction of DNA synthesis consistent with a wild-type activity at this temperature.
We have used several different assays to measure the function of mutant p53s, summarized in Table 3 . It is tempting to correlate intermediate phenotypes in some of these assays, for example BL37 and Raji retain suppressor activity in BRK cells and retain the strongest E6 binding of all the mutants whereas Ramos is transforming in the BRK assay and most defective for E6 binding and degradation. This, however, is not reflected in the Akata DNA synthesis assay where none of the p53 mutants, including Raji and Ramos, are distinguishably different. At present we think that the assays are too complex to allow much detailed interpretation beyond demonstrating loss of wild-type function and offering useful clues to the underlying biochemical changes in p53 function resulting from the mutations. So, in summary, these studies indicate that all the BL p53 mutants are functionally altered and that the in vitro assays may prove useful in the rapid screening for functional alterations of p53 mutants.
